Collapse all
The Business Model Canvas reveals a high-value, high-risk clinical model that shifts mental health care from chronic management to acute intervention. Success depends on navigating strict legal frameworks and managing high operational costs associated with intensive 1-on-1 clinical supervision.
4 Pharmaceutical Suppliers Authorized providers of research-grade synthetic psilocybin to ensure dosage consistency and legal compliance. Regulatory Bodies FDA or regional health authorities (e.g., Oregon Health Authority) to maintain licensure and operational legality. Referring Psychiatrists External mental health professionals who identify and refer patients who have failed multiple SSRI trials. Research Institutions Academic partners to validate long-term outcomes and contribute to evidence-based protocol refinement. 4 Clinical Screening Rigorous psychiatric evaluation to exclude patients with instability or contraindications to prevent adverse events. Supervised Dosing Sessions Managing high-dose (25mg) psilocybin sessions with constant licensed clinician supervision for safety. Psychotherapeutic Integration Conducting structured preparatory and post-session integration therapy to solidify antidepressant effects. Outcome Monitoring Tracking MADRS scores and functional disability metrics to prove efficacy to payers and patients. 4 Licensed Clinicians Specialized therapists and psychiatrists trained in psychedelic-assisted therapy (PAT) protocols. Clinical Infrastructure Safe, controlled physical environments designed for intense psychedelic experiences. Legal Licenses Specific permits to handle and administer Schedule I substances within legal jurisdictions. Evidence-Based Protocols Standardized dosing and therapy schedules derived from phase 2 clinical trials. 4 Rapid Symptom Reduction Offering a faster onset of action (days vs. months) compared to traditional SSRIs for TRD patients. Alternative for TRD Providing a viable clinical path for patients who have failed two or more standard antidepressant trials. Cost-Effectiveness for Payers Reducing long-term chronic care costs by replacing daily medication with a short-term acute intervention. Improved QALYs Increasing quality-adjusted life years through significant and sustained reduction in depressive scores. 3 High-Touch Clinical Care Intensive, personalized support during the preparatory, dosing, and integration phases. Trust-Based Referrals Maintaining professional relationships with referring psychiatrists to ensure a steady patient pipeline. Patient Safety Monitoring Continuous engagement to mitigate risks of 'bad trips' or self-harm through strict supervision. 3 Psychiatric Referrals Direct referral pipelines from psychiatrists treating patients with treatment-resistant depression. Health Insurance Networks Integration into provider networks for private and public health insurance reimbursement. Clinical Trial Registries Attracting patients through official research protocols and trial recruitment platforms. 3 TRD Patients Individuals with moderate-to-severe MDD who have failed multiple traditional antidepressant trials. Private Health Insurers Payers interested in reducing the long-term cost of chronic depression management. Psychiatric Hospitals Institutions seeking specialized intervention options for their most difficult-to-treat patients. 4 Clinical Labor High costs due to the requirement for 1-on-1 or 2-on-1 clinician-to-patient ratios during sessions. Compliance and Legal Ongoing costs for maintaining strict regulatory adherence and legal licensing. Facility Overhead Costs associated with maintaining specialized, safe clinical environments for dosing. Pharmaceutical Procurement Costs of acquiring high-purity, synthetic psilocybin through authorized channels. 3 Treatment Package Fees Flat-fee pricing for a complete protocol (e.g., 3 prep sessions, 2 dosing sessions, 6 integration sessions). Insurance Reimbursements Per-session or per-episode payments from health insurance providers based on QALY gains. Research Grants Funding from government or private entities to conduct clinical trials and gather efficacy data. The model requires a clear definition of how value is captured, specifically regarding insurance reimbursement and the cost of high-intensity clinical support. · Generated 2026-09-11 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated